Randomized Aldactone Evaluation Study

Randomized Aldactone Evaluation Study
Name	Randomized Aldactone Evaluation Study
Acronym	RALES
Phase	III
Status	Completed
Intervention	Spironolactone
Condition	Heart failure
Start date	1990
Completion date	1999

Randomized Aldactone Evaluation Study

The Randomized Aldactone Evaluation Study was a landmark randomized controlled trial evaluating spironolactone for severe heart failure. It influenced practice across cardiology and influenced policy, guideline, and formulary decisions in cardiology centers and institutions in Europe and North America. The trial's findings were disseminated through major scientific fora and led to discussion among clinicians, regulators, and pharmacology experts.

Background

The trial was conceived in the context of evolving evidence about neurohormonal modulation in heart failure and followed seminal work by investigators in cardiology and internal medicine settings. Influences included earlier randomized trials and cohort studies from academic centers, teaching hospitals, and cardiovascular research networks. Key debates at the time involved the roles of aldosterone and the renin–angiotensin–aldosterone system in progressive myocardial remodeling, with commentary appearing in clinical journals and discussed at meetings of major societies and academies.

Study Design

The trial used a randomized, double‑blind, placebo‑controlled design enrolling patients with symptomatic severe heart failure on background therapy. Eligibility criteria and randomization procedures were overseen by steering committees and independent data monitoring boards comprising clinicians from university hospitals and specialty clinics. Endpoints included all‑cause mortality and hospitalizations adjudicated by blinded committees. Statistical analysis plans were predefined and utilized intention‑to‑treat principles, with interim analyses guided by data safety monitoring processes common to large multicenter cardiovascular trials.

Results

The study reported a statistically significant reduction in mortality and heart failure hospitalizations among patients assigned to spironolactone compared with placebo. Absolute and relative risk reductions were highlighted alongside Kaplan–Meier survival estimates and hazard ratios produced from proportional hazards models. Results generated extensive discussion in editorials, letters, and subsequent meta‑analyses conducted by academic groups, guideline committees, and health technology assessment programs across multiple countries.

Safety and Adverse Events

Safety monitoring identified hyperkalemia and renal impairment as key adverse events of interest, with rates monitored through scheduled laboratory assessments and clinical follow‑up. The trial protocol specified dose adjustments, discontinuation criteria, and reporting pathways for serious adverse events to regulatory agencies and ethics committees. Post‑trial pharmacovigilance and registry data from specialist centers and population health databases further characterized safety signals and informed risk‑mitigation strategies recommended by professional societies.

Subgroup Analyses

Prespecified and exploratory subgroup analyses explored heterogeneity of treatment effect by age, sex, baseline ejection fraction, comorbidity profiles, and concomitant medications. These subgroup assessments were reported with caution about power and multiplicity, and subsequent pooled analyses and individual patient data meta‑analyses by research consortia and collaborative networks examined consistency of benefit across diverse patient populations and practice settings.

Clinical Impact and Guidelines Integration

Following publication, professional societies and guideline panels considered the trial when updating recommendations for heart failure management. Clinical pathways, formularies, and stewardship programs at hospitals and health systems incorporated the trial's evidence into prescribing algorithms, with educational outreach by national specialty societies and academic centers. Implementation also involved payers, health technology assessment bodies, and regulatory authorities in discussions about labeling, monitoring, and post‑marketing commitments that shaped contemporary practice.

Category:Clinical trials